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Figure S8 Post-treatment effect on efficacy outcomes 12 Bias due to deviations from intended interventions: There were deviations from the intended interventions (in terms of adherence or use that were likely to impact on the outcome: "At the time celecoxib was suspended, 5.1% of the placebo arm and 3.1% of the celecoxib arm participants had completed taking the intervention"; adherence not clearly reported.
Bias due to missing outcome data: Differential missing data (different proportion of or different reasons for missing data in compared groups) at different time intervals. A high degree of missing data for the evaluation of primary outcomes (we used primary efficacy outcomes reported within 1 year of discontinuing intervention as reported by study authors)
Figure S2: Sensitivity analysis-per protocol completer analysis
Per protocol completer analysis; Sel/Cel: those subjects who underwent colonoscopy surveillance at the prespecified time period per protocol at 3.5 years (as per protocol follow-up duration is around 3-5 years). ⨁⨁◯◯ LOW #among three trials included in the analysis, Sel/Cel is considered to be at high ROB. Since, detection of significant changes in efficacy was not found for any outcomes after excluding Sel/Cel trial, we decided to grade our analysis as with no serious ROB; $ strong association, a RR<0.05 based on direct evidence, with no plausible confounders; *the 95% CI overlaps no effect Low risk group includes patients with 1-2 small (<1 cm) tubular adenoma(s) with low grade dysplasia, and estimated risk of advanced adenomas of 74 per 1000 individuals without intervention; high risk group includes patients with 1 cm or larger, with villous or tubule-villous histology, with high grade dysplasia, and/or with intra-mucosal carcinoma or invasive cancer, and estimated risk of advanced adenomas of 163 per 1000 individuals without intervention.
Serious adverse events were defined as events resulting in death, hospital admission because of an adverse event, severe gastrointestinal bleeding, CV or non-CV complications, or discontinuation of intervention due to an adverse event or events that were defined as serious or severe by study authors. 190 per 1000 events graded as serious or severe by original study authors over same time period without any intervention.
Serious CV events defined as the composite of CV death, myocardial infarction, stroke, heart failure, thromboembolic event or defined as serious CV event by the study investigators. 34 per 1000 events graded as serious CV events by original study authors over same time period without any intervention. 
